Rapport Therapeutics (RAPP) has come into focus after being added to several Russell growth indices, a shift that can draw fresh attention from index tracking funds and benchmark oriented investors.

At a share price of $38.97, Rapport Therapeutics has seen short term share price returns ease slightly over the past week, while its 30 day and year to date share price returns remain positive. The 1 year total shareholder return of 223.67% points to strong earlier momentum that recent index additions and routine insider selling have not fully undone.

If you are looking beyond a single CNS focused stock, this could be a good moment to see what else is moving in healthcare related AI, starting with the 40 healthcare AI stocks.

With Rapport Therapeutics now in multiple Russell growth indices, a 1 year total shareholder return above 200% and a recent share price near $39, the key question is whether valuation still lags the story or if the market is already pricing in future growth.

Preferred Price-to-Book Multiple of 4x: Is It Justified?

With Rapport Therapeutics trading at a P/B of 4x compared with the US Pharmaceuticals industry average of 2.4x, the stock is priced at a clear premium to the broader group, even after the strong 1 year total shareholder return and recent index inclusion.

The price to book ratio compares the company’s market value with its net assets, so a higher P/B generally implies investors are willing to pay more for each dollar of equity on the balance sheet. For a clinical stage biopharmaceutical company like Rapport Therapeutics, where current revenue of $20.0 million and a reported net loss of $107.277 million do not yet reflect potential future products, investors often focus on research assets, management quality and pipeline progress rather than current earnings.

In this case, the 4x P/B suggests the market is assigning a richer valuation than the industry average, even though Rapport Therapeutics is currently unprofitable, has a negative return on equity of 22.75% and is forecast to remain loss making over the next 3 years while earnings are expected to decline by 16.2% per year. At the same time, the stock is trading below the peer average P/B of 5.4x, which places it at a discount to a closer comparison group of similar companies and highlights how sentiment among more directly comparable stocks can differ from the broader industry benchmark.

Against this backdrop, the higher P/B relative to the industry and lower P/B relative to peers draw a clear line between how the wider market and closer comparables are pricing CNS focused, early stage biopharmaceuticals and where Rapport Therapeutics currently sits within that spectrum.

Result: Price-to-book of 4x (OVERVALUED) compared with the broader US Pharmaceuticals industry, but at a discount relative to the peer average.

However, the story around Rapport Therapeutics could shift if clinical data disappoints or if the company’s continuing net losses pressure sentiment on its current valuation.

Next Steps

Does the mix of strong past returns and a richer P/B for Rapport Therapeutics leave you optimistic or cautious? Act sooner rather than later, review the full picture, and weigh both the concerns and potential upside using the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Rapport Therapeutics?

Do not stop with Rapport Therapeutics. Broaden your watchlist with stocks that bring different strengths to your portfolio using targeted screeners designed to surface clear ideas.

• Explore potential upside with carefully filtered smaller companies by checking out 20 elite penny stocks with strong financials.
• Strengthen the core of your portfolio with businesses that combine quality and attractive pricing through the 44 high quality undervalued stocks.
• Focus on staying power in tougher markets by using the 74 resilient stocks with low risk scores to review companies with lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.